Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT05551507 | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07340164 | Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy(TROY) | recruiting | Phase 2 | 116 | Yonsei UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Eli Avisar, MDOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | recruiting | Phase 2 | 174 | Michael A. O'DonnellOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03609216 | Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | active not recruiting | Phase 2 | 237 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 46 | Matthew GalskyOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07514494 | Intensification Treatment of Ovarian Cancer by PIPAC(PrimPIPAC) | recruiting | Phase 2 | 160 | Moscow Regional Oncological DispensaryOTHER_GOV | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05335993 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | active not recruiting | Phase 2 | 10 | CanariaBio Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 88 | CanariaBio Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06290193 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer(VG-INFUSE Tria) | completed | Phase 1 / Phase 2 | 20 | Ding-Wei YeOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03947151 | Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer(DEGASTIM) | completed | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06704191 | In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | recruiting | Phase 1 / Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | recruiting | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480954 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)(DUAL-OV-CAR-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07109414 | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | active not recruiting | Phase 2 / Phase 3 | 380 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01616875 | Bristol Bladder Trial | completed | Phase 2 | 28 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | active not recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 4, 2026source: clinicaltrials